The evaluation and management of refractory neurogenic overactive bladder
- PMID: 25118853
- DOI: 10.1007/s11934-014-0444-z
The evaluation and management of refractory neurogenic overactive bladder
Abstract
Patients with neurologic disease commonly develop overactive bladder (OAB) symptoms of urgency, frequency, and/or urge incontinence that remain bothersome despite oral pharmacologic therapy. Management of refractory OAB in the neurogenic population is a complex issue with no uniform treatment strategy. When treatment fails or patients generally are dissatisfied with the adverse effects of oral therapy, available options include sacral neuromodulation, percutaneous tibial nerve stimulation (PTNS), botulinum toxin injections, and lower urinary tract reconstruction such as augmentation cystoplasty. A thorough knowledge and understanding of available and emerging treatment options for neurogenic detrusor overactivity is paramount to assisting clinicians in choosing an appropriate treatment. This article reviews the non-pharmacologic treatment options for neurogenic OAB, mainly botulinum toxin, neuromodulation, and lower urinary tract reconstruction, and discusses important relevant studies.
Similar articles
-
The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?Curr Opin Urol. 2015 Jul;25(4):305-10. doi: 10.1097/MOU.0000000000000180. Curr Opin Urol. 2015. PMID: 26049873 Review.
-
Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).Neurourol Urodyn. 2014 Jul;33 Suppl 3:S21-5. doi: 10.1002/nau.22631. Neurourol Urodyn. 2014. PMID: 25042139 Review.
-
Overactive Bladder.Obstet Gynecol Clin North Am. 2016 Mar;43(1):59-68. doi: 10.1016/j.ogc.2015.10.002. Obstet Gynecol Clin North Am. 2016. PMID: 26880508 Review.
-
Management of refractory OAB in the non-neurogenic patient.Curr Urol Rep. 2014 Sep;15(9):438. doi: 10.1007/s11934-014-0438-x. Curr Urol Rep. 2014. PMID: 25015301 Review.
-
What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?Curr Urol Rep. 2018 Sep 8;19(11):91. doi: 10.1007/s11934-018-0842-8. Curr Urol Rep. 2018. PMID: 30196438 Review.
Cited by
-
Nocturia: Current Evaluation and Treatment for Urology.Curr Urol Rep. 2015 Sep;16(9):66. doi: 10.1007/s11934-015-0533-7. Curr Urol Rep. 2015. PMID: 26231263 Review.
-
Personalised 3D-Printed Mucoadhesive Gastroretentive Hydrophilic Matrices for Managing Overactive Bladder (OAB).Pharmaceuticals (Basel). 2023 Feb 28;16(3):372. doi: 10.3390/ph16030372. Pharmaceuticals (Basel). 2023. PMID: 36986471 Free PMC article.
-
Our experience with ureterocystoplasty in bilateral functional kidneys.Turk J Urol. 2019 Dec;45(Supp. 1):S78-S83. doi: 10.5152/tud.2018.42223. Epub 2018 Aug 17. Turk J Urol. 2019. PMID: 30201076 Free PMC article.
-
A comparison of sacral neuromodulation vs. transvaginal electrical stimulation for the treatment of refractory overactive bladder: the impact on quality of life, body image, sexual function, and emotional well-being.Prz Menopauzalny. 2019 Jun;18(2):89-93. doi: 10.5114/pm.2019.86834. Epub 2019 Jun 28. Prz Menopauzalny. 2019. PMID: 31485205 Free PMC article. Review.
-
Neuromodulation in neurogenic bladder.Transl Androl Urol. 2016 Feb;5(1):117-26. doi: 10.3978/j.issn.2223-4683.2015.12.01. Transl Androl Urol. 2016. PMID: 26904417 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical